Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination…

By D. Eberhard, B. Johnson, L. Amler, A. Goddard, Sherry Heldens, R. Herbst, William L. Ince, P. Jänne, T. Januario, David H. Johnson and 9 more. Journal of Clinical Oncology, 2005

1,504 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3c41fe969bd5cac233cbb0cd0770846ed67e9c6c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jin-Yuan Shih
2. John N. Weinstein
3. William Pao
4. S. Rosen
5. Kevin R. Coombes
6. Jing Wang
7. C. Der
8. P. Roberts

In Pulmonary and Respiratory Medicine

1. Jin-Yuan Shih
2. William Pao
3. S. Lippman
4. C. Der
5. P. Roberts

Citations in the corpus

• An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance (2012, methodology): “Analysis was limited to the EGFR wild-type/KRASwild-type patients, as there are no validated markers of response to EGFR inhibitors in that group [whereas EGFR mutation is associated with response and KRAS mutation with resistance (3, 4, 43)].”
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors (2009, neutral): “…supported by a subset analysis from a phase III trial of erlotinib plus chemotherapy versus chemotherapy alone, which revealed significantly longer survival times in patients with EGFR mutations compared with those who had wildtype EGFR when treated with chemotherapy alone (Eberhard et al., 2005).”
• Identification of a Novel Biomarker, SEMA5A, for Non–Small Cell Lung Carcinoma in Nonsmoking Women (2010, background): “Cancer Control 2006;13:129–40. erhard DA, Johnson BE, Amler LC, et al. Mutations in the epiderl growth factor receptor and in KRAS are predictive and prognosindicators in patients with non-small-cell lung cancer treated with motherapy alone and in combination with erlotinib.”
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, background): “Five studies involved chemotherapy either with or without an EGFR TKI.124,137,138,149,155 Thirty-one of the studies reported OS.”